Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichiro Kadonaga

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
PET Clinics|March 30, 2023
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical ConsiderationsKazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Solid-Phase Oligosaccharide Synthesis with Highly Complexed Peptidoglycan FragmentsYuichiro Kadonaga, Ning Wang, Atsushi Shimoyama, et al.
Angewandte Chemie (International Ed. in English)|May 7, 2019
Enantioselective Total Synthesis of (+)-Jungermatrobrunin AJinbao Wu, Yuichiro Kadonaga, Benke Hong, et al.
Journal of the American Chemical Society|January 23, 2020
Protecting-Group-Free Syntheses of <i>ent</i>-Kaurane Diterpenoids: [3+2+1] Cycloaddition/Cycloalkenylation ApproachJin Wang, Benke Hong, Dachao Hu, et al.
Journal of the American Chemical Society|October 2, 2019
Synthesis of Cage-Shaped Aluminum Aryloxides: Efficient Lewis Acid Catalyst for Stereoselective Glycosylation Driven by Flexible Shift of Four- to Five-CoordinationDaiki Tanaka, Yuichiro Kadonaga, Yoshiyuki Manabe, et al.
Journal of Nanobiotechnology|July 29, 2021
Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapyHiroki Kato, Xuhao Huang, Yuichiro Kadonaga, et al.
Pharmaceutics|December 23, 2022
Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous InjectionXuhao Huang, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2022
Targeted α-therapy using astatine (<sup>211</sup>At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compoundTadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, et al.
Organic Letters|December 21, 2021
Revisiting Glycosylations Using Glycosyl Fluoride by BF<sub>3</sub>·Et<sub>2</sub>O: Activation of Disarmed Glycosyl Fluorides with High Catalytic TurnoverYoshiyuki Manabe, Takuya Matsumoto, Yuka Ikinaga, et al.
International Journal of Molecular Sciences|November 27, 2024
Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kentaro Hisada, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
PET Clinics|March 30, 2023
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical ConsiderationsKazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, et al.
Molecules (Basel, Switzerland)|July 12, 2025
Solid-Phase Oligosaccharide Synthesis with Highly Complexed Peptidoglycan FragmentsYuichiro Kadonaga, Ning Wang, Atsushi Shimoyama, et al.
Angewandte Chemie (International Ed. in English)|May 7, 2019
Enantioselective Total Synthesis of (+)-Jungermatrobrunin AJinbao Wu, Yuichiro Kadonaga, Benke Hong, et al.
Journal of the American Chemical Society|January 23, 2020
Protecting-Group-Free Syntheses of <i>ent</i>-Kaurane Diterpenoids: [3+2+1] Cycloaddition/Cycloalkenylation ApproachJin Wang, Benke Hong, Dachao Hu, et al.
Journal of the American Chemical Society|October 2, 2019
Synthesis of Cage-Shaped Aluminum Aryloxides: Efficient Lewis Acid Catalyst for Stereoselective Glycosylation Driven by Flexible Shift of Four- to Five-CoordinationDaiki Tanaka, Yuichiro Kadonaga, Yoshiyuki Manabe, et al.
Journal of Nanobiotechnology|July 29, 2021
Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapyHiroki Kato, Xuhao Huang, Yuichiro Kadonaga, et al.
Pharmaceutics|December 23, 2022
Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous InjectionXuhao Huang, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2022
Targeted α-therapy using astatine (<sup>211</sup>At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compoundTadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, et al.
Organic Letters|December 21, 2021
Revisiting Glycosylations Using Glycosyl Fluoride by BF<sub>3</sub>·Et<sub>2</sub>O: Activation of Disarmed Glycosyl Fluorides with High Catalytic TurnoverYoshiyuki Manabe, Takuya Matsumoto, Yuka Ikinaga, et al.
International Journal of Molecular Sciences|November 27, 2024
Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kentaro Hisada, et al.
Pageof 2